Document is current

Article History

Accepted: 15 October 2020

First Online: 3 December 2020

Competing interests

: J.B. reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva and Uriach and other fees from KYomed-Innov and MASK-air outside the submitted work. S.B.-A. reports grants from TEVA and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan, Sanofi and TEVA outside the submitted work. C.B. reports personal fees from ALK, Mylan, GlaxoSmithKline, Sanofi, Novartis and AstraZeneca. G.W.C. reports having received research grants as well as being a lecturer or having received advisory board fees from A.Menarini, ALK-Abelló, Allergy Therapeutics, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, GlaxoSmithKline, Hal Allergy, Mylan, Merck, Merck Sharp & Dohme Mundipharma, Novartis, Regeneron, Roche, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, UCB Pharma, Uriach Pharma, Valeas and Vibor-Pharma. I.B reports personal fees from Menarini, Mundipharma, Novartis, GlaxoSmithKline, Sanofi-Genzyme, AstraZeneca and Boehringer Ingelheim outside the submitted work. E.M. reports personal fees from AstraZeneca, Chiesi, Novartis and Sanofi outside the submitted work. O.P. reports research grants from Inmunotek S.L. and Novartis and fees for giving scientific lectures from Allergy Therapeutics, Amgen, AstraZeneca, Diater, GlaxoSmithKline S.A., Inmunotek S.L., Novartis, Sanofi-Genzyme and Stallergenes, and has participated in advisory boards for Novartis and Sanofi-Genzyme. G.K.S. reports personal fees from ALK, Bayer, GlaxoSmithKline and Mylan, outside the submitted work, and is British Society for Allergy and Clinical Immunology Rhinitis Guidelines Chair and European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) Lead for allergic rhinitis. All other authors declare no competing interests.